NAV4694 Clinical Studies

NAV4694 has been studied in several clinical trials. Clinical studies have included more than 70 patients, both suspected AD patients and healthy volunteers, through Phase IIa trials. No significant adverse events have been observed to date. Results suggest that NAV4694 has the ability to image patients quickly and safely with high sensitivity. Importantly, NAV4694 seems to exhibit low background and white matter uptake, thereby providing clear images of Beta-amyloid deposits.

NAV4694 is currently being evaluated in a Phase 2b trial for monitoring progression of Mild Cognitive Impairment to Alzheimer’s Disease and the autopsy-based, Phase 3 registration trial in Alzheimer’s disease.  For more information about these clinical studies please refer to the Clinical website.

You can view a bibliography of NAV4694 pre-clinical and clinical research in our Publications section of the website.